New Study for People with Stage 4 Non-Small Cell Lung Cancer

There is a new clinical study looking for patients with Stage IV non-small cell lung cancer who have already been treated with chemotherapy. The purpose of this study is to compare the new investigational medicine versus the standard-of-care treatment with respect to life expectancy outcomes.
More about the study:
The study drug (LY2835219) is administered by Tablets, Pills, or Capsules.

• At least 193 people have already taken this drug in clinical trials.
• There will be 550 participants in this trial, at 20 sites around the world.

If you are interested, please find the full study details and eligibility criteria listed here.
Eligibility Criteria:
Participants must:

• be at least 18 years old
• have a diagnosis of stage IV non-small cell lung cancer (Stage IV means the cancer has spread to distant tissues or organs)
• have tumors with KRAS mutations, if known
• have already had chemotherapy for this tumor

Participants must not:

• be pregnant or lactating
• have HIV, Hepatitis B or C, or a history of cardiac arrest

Please complete the online questionnaire to check if you’re eligible for the trial.
If you’re not familiar with clinical trials, here are some FAQs:

What are clinical trials?

Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.

Why participate in a clinical trial?

You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.
Learn why I’m talking about Clinical Trials